化瘀通脉颗粒干预经皮腔内冠状动脉介入治疗术后再狭窄的临床研究

Study of Huayutongmai Granule in Restenosis after Percutaneous Coronary Intervention

目的观察化瘀通脉颗粒干预冠心病经皮腔内冠状动脉介入治疗(PCI)术后再狭窄的临床效果。方法将60例冠心病经PCI治疗患者随机分为对照组和治疗组,治疗组31例,对照组29例。对照组按照常规治疗方法治疗,治疗组在对照组药物基础上加服化瘀通脉颗粒治疗。两组疗程均为6个月。结果治疗组总有效率为83.87%,明显高于对照组的62.07%(P<0.05)。治疗组中医症状积分降低较对照组更加明显(P<0.05)。治疗组心绞痛和临床再狭窄人数明显少于对照组(P<0.05);冠脉CTA再狭窄发生人数治疗组也少于对照组(P<0.05)。结论化瘀通脉颗粒具有预防PCI术后再狭窄的作用。

Objective： To investigate the effect of the Huayutongmai Granule in the restenosis after percutaneous coronary intervention（PCI）. Methods： 60 cases of coronary artery disease after PCI treatment were divided into the control group with conventional treatment and the treatment group with the conventional treatment combined with Huayutongmai Granule. After 6 months,some indices were compared between 2 groups. Results： The total effective rate in the treatment group with 83.87% was higher than that in the control group with 62.07%（P〈0.05）. The reduction of the symptomes score in the treatment group was more obvious than that in the control group a（P〈0.05）. Meanwhile,the restenosis cases,the angina patients and the coronary CTA restenosis peopele in the treatment group were lower significantly than those in the control group（P〈0.05）. Conclusion： The Huayutongmai Granule has the effect of the prevention of PCI postoperative restenosis.